This project measured physiological and cognitive variables to determine the effectiveness of Theacrine (TCR) as a stimulant at doses greater than those previously tested. The study will be the first TCR study to use doses relative to body weight and will investigate impacts on regular caffeine consumers. A secondary aim of the study is to determine the impact of acute TCR supplementation on salivary cortisol and sAA, two physiological measures of stress and sympathetic nervous system activation. The findings of the study will provide new insight into the effects of higher TCR dosages, contributing to the analysis of TCR as a caffeine alternative for individuals with hypertension, tachycardia, or healthy caffeine consumers wanting to avoid a stimulant with adverse or habitual effects

Inclusion Criteria:

- habitual caffeine consumer (≥2 days/week)

Exclusion Criteria:

• existing heart disease or conditions (cardiovascular and/or heart disease, stroke, diabetes hypertension, tachycardia)
• a smoker
• allergy to caffeine or Theacrine
• caffeine sensitivity (negative symptoms such as jitters after consuming low doses)
• pregnant
• on heart or blood pressure medication

all individual deidentified participant data that underlie results in a publication

IPD data sharing will be available starting 6 months after publication

The data generated and analyzed during this study will be available starting 6 months after publication upon request from the principal investigator